Bulk Pharmaceutical API Sources for ACTOS

Bulk Pharmaceutical API Sources for ACTOS

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-002-508-211
Hangzhou APIChem Technology		AC-1021
Amadis Chemical		A801204
Amadis Chemical		A802277
AKos Consulting & Solutions		AKOS015894953
Vitas-M Laboratory		STL309607

Actos Bulk API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the current landscape of bulk Active Pharmaceutical Ingredient (API) sources for pioglitazone hydrochloride, the API in Actos. It examines key manufacturers, their production capacities, regulatory compliance, and geographical distribution. The analysis aims to provide a data-driven overview for procurement and strategic planning within the pharmaceutical sector.

Who are the Primary Bulk API Manufacturers for Pioglitazone Hydrochloride?

The global supply chain for pioglitazone hydrochloride API is primarily concentrated among a select group of manufacturers, predominantly located in India and China. These companies have established production facilities and have secured regulatory approvals necessary for supplying to major pharmaceutical markets.

• Indian Manufacturers: India is a significant hub for generic API production, including pioglitazone hydrochloride. Key players include:

  • Dr. Reddy's Laboratories: A large, integrated pharmaceutical company with extensive API manufacturing capabilities. They operate multiple GMP-certified facilities [1].
  • Laurus Labs: Known for its strong focus on backward integration and cost-effective API production. Laurus Labs has substantial capacity for various therapeutic classes [2].
  • Divi's Laboratories: A leading producer of APIs and intermediates, with a strong regulatory track record and significant production scale [3].
  • Aarti Drugs: This company manufactures a range of APIs, including anti-diabetic agents, and has a well-established export market [4].
  • Granules India: Focuses on affordable and high-quality pharmaceutical ingredients, with a growing presence in regulated markets [5].

• Chinese Manufacturers: China also plays a crucial role in the global API supply chain, with several companies exporting pioglitazone hydrochloride.

  • Zhejiang NHU Co., Ltd.: A major chemical and pharmaceutical company with a broad portfolio of APIs and finished dosage forms [6].
  • Jiangsu Zhongbang Pharmaceutical Co., Ltd.: Specializes in pharmaceutical intermediates and APIs, serving both domestic and international markets.
  • Shandong Xinhua Pharmaceutical Co., Ltd.: One of China's older and larger pharmaceutical enterprises, with a significant API production capacity.

• Other Regions: While India and China dominate, some API manufacturers in other regions may also supply pioglitazone hydrochloride, though often on a smaller scale or for specific regional markets.

What are the Production Capacities and Scales?

Estimates of specific production capacities for pioglitazone hydrochloride API by individual manufacturers are proprietary. However, the overall production scale can be inferred from the market presence and export volumes of these key players.

• Annual Global Demand: While precise figures are not publicly disclosed, the global demand for pioglitazone hydrochloride API is substantial, driven by the continued use of Actos (and its generic equivalents) in managing type 2 diabetes. Market research reports indicate that the global pioglitazone market is valued in the hundreds of millions of dollars annually, suggesting a significant volume of API is required.
• Manufacturer Scale: Leading Indian and Chinese manufacturers typically possess capacities ranging from several metric tons to hundreds of metric tons per year for high-volume APIs. These facilities are designed for large-scale, continuous production to meet global demand efficiently.
• Flexibility: Many API manufacturers maintain flexible production lines that can be switched between different products. This allows them to adjust output based on market demand and contractual obligations.

What are the Key Regulatory Approvals and Compliance Standards?

Access to major pharmaceutical markets, including the United States, European Union, and Japan, necessitates adherence to stringent regulatory standards and the successful completion of regulatory audits.

• Good Manufacturing Practices (GMP): All reputable API manufacturers must comply with GMP standards. In the U.S., this is overseen by the Food and Drug Administration (FDA); in Europe, by the European Medicines Agency (EMA) and national competent authorities; and in Japan, by the Pharmaceuticals and Medical Devices Agency (PMDA).
• Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory agencies. A DMF is a submission to the FDA that provides confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.
  • U.S. DMFs: Many Indian and Chinese API manufacturers hold U.S. DMFs for pioglitazone hydrochloride, which are periodically reviewed by the FDA.
  • European CEPs (Certificates of Suitability to the Monographs of the European Pharmacopoeia): This is a common route for API manufacturers to demonstrate compliance with European Pharmacopoeia standards and to facilitate marketing authorization applications in Europe.
• Inspections: Facilities are subject to periodic inspections by regulatory authorities. Successful inspections are critical for maintaining supply agreements with pharmaceutical companies marketing finished dosage forms. Key audit findings or deficiencies can lead to import alerts or other enforcement actions.
• Pharmacopoeial Standards: The API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).

Table 1: Key Regulatory Filings for Pioglitazone Hydrochloride API

Manufacturer	U.S. DMF Status	European CEP Status	Key Regulatory Audits
Dr. Reddy's Laboratories	Filed/Approved	Available	FDA, EMA, PMDA, WHO
Laurus Labs	Filed/Approved	Available	FDA, EMA, PMDA, TGA (Australia), Health Canada
Divi's Laboratories	Filed/Approved	Available	FDA, EMA, PMDA, KFDA (Korea), SFDA (China)
Aarti Drugs	Filed/Approved	Available	FDA, EMA
Granules India	Filed/Approved	Available	FDA, EMA, PMDA
Zhejiang NHU Co., Ltd.	Filed/Approved	Available	NMPA (China), FDA, EMA
Jiangsu Zhongbang Pharm.	Filed/Approved	Available	NMPA (China), FDA
Shandong Xinhua Pharm.	Filed/Approved	Available	NMPA (China), FDA, EMA

Note: "Available" for CEP means that a certificate has been issued, indicating successful assessment against the European Pharmacopoeia monograph. Specific DMF numbers and their status are publicly searchable on regulatory agency databases.

What are the Geographical Distribution of API Manufacturing?

The geographical distribution of pioglitazone hydrochloride API manufacturing is heavily concentrated in Asia, with India and China serving as the predominant sourcing regions.

• India:

  • Advantages: Cost-effective manufacturing, strong technical expertise, well-established regulatory compliance infrastructure, and a large pool of skilled labor. Many Indian companies have extensive experience supplying to highly regulated markets.
  • Key Manufacturing Hubs: Gujarat and Andhra Pradesh are significant pharmaceutical manufacturing states in India.

• China:

  • Advantages: Large-scale production capabilities, competitive pricing, and a significant presence in the global chemical supply chain.
  • Key Manufacturing Hubs: Provinces like Zhejiang, Jiangsu, and Shandong are major centers for pharmaceutical and chemical production.

• Other Regions: While less prominent for bulk pioglitazone HCl, API manufacturing exists in Europe and North America. However, these operations are often focused on higher-value, niche APIs or operate at a smaller scale, making them less competitive for high-volume generic APIs like pioglitazone hydrochloride unless there are specific supply chain security or quality concerns driving diversification.

What are the Supply Chain Risks and Mitigation Strategies?

Sourcing bulk APIs, particularly from a concentrated geographical region, presents inherent risks that require careful management.

• Geopolitical Instability: Political tensions or trade disputes between major sourcing countries and key consuming nations can disrupt supply chains.

  • Mitigation: Diversification of suppliers across different geographical regions, even if it entails slightly higher costs. Building strategic partnerships with multiple qualified manufacturers.

• Regulatory Changes and Audits: Stricter regulatory enforcement or unfavorable changes in import/export regulations can impact API availability. A single failed regulatory inspection can halt supply from a key manufacturer.

  • Mitigation: Rigorous supplier qualification processes that include thorough regulatory history reviews and ongoing monitoring of compliance. Maintaining close relationships with regulatory agencies and industry bodies.

• Quality Control Issues: Batch failures, contamination, or deviations from GMP can lead to product recalls and supply disruptions.

  • Mitigation: Implementing robust incoming material testing protocols. Conducting regular, independent quality audits of manufacturing sites. Requiring detailed quality agreements with suppliers.

• Natural Disasters and Pandemics: Events like natural disasters or global health crises can disrupt production and logistics.

  • Mitigation: Maintaining adequate safety stock of API. Developing contingency plans for alternative logistics and production sites.

• Intellectual Property (IP) and Patent Landscape: While the primary patents for pioglitazone have expired, ongoing litigation or the emergence of new process patents could theoretically impact manufacturing.

  • Mitigation: Thorough patent landscape analysis to identify any existing or potential IP challenges related to manufacturing processes. Ensuring freedom-to-operate for chosen API suppliers.

What are the Cost Drivers and Pricing Trends?

The cost of pioglitazone hydrochloride API is influenced by several factors:

• Raw Material Costs: The cost of precursor chemicals and intermediates is a primary determinant. Fluctuations in the prices of these upstream materials directly impact API production costs.
• Manufacturing Scale and Efficiency: Larger production volumes and more efficient manufacturing processes generally lead to lower per-unit costs.
• Regulatory Compliance Costs: Investment in GMP-compliant facilities, quality control, and regulatory filings adds to the overall cost.
• Labor Costs: Wage rates in manufacturing regions play a significant role.
• Energy and Utilities: The cost of electricity, water, and other utilities is a substantial component of manufacturing expenses.
• Logistics and Transportation: Shipping costs, import duties, and tariffs impact the landed cost of the API.

Pricing Trends:

• Genericization Impact: Following patent expiry, the market for pioglitazone hydrochloride has been highly competitive due to genericization. This has driven down API prices significantly over the years.
• Supplier Competition: Intense competition among a large number of API manufacturers, particularly in India and China, exerts downward pressure on prices.
• Volume Commitments: Pharmaceutical companies that can commit to large, long-term purchase volumes often negotiate more favorable pricing.
• Quality Premiums: While price is a major factor, there is a premium associated with APIs from suppliers with a consistently strong regulatory track record and a history of high-quality output.

Key Takeaways

• The global supply of pioglitazone hydrochloride API is predominantly sourced from India and China, with manufacturers like Dr. Reddy's Laboratories, Laurus Labs, Divi's Laboratories, Zhejiang NHU Co., Ltd., and Shandong Xinhua Pharmaceutical Co., Ltd. being key players.
• Regulatory compliance, specifically adherence to GMP and successful filings like US DMFs and European CEPs, is critical for market access and supplier qualification.
• Supply chain risks, including geopolitical factors, regulatory changes, quality control issues, and natural disasters, necessitate strategic diversification of suppliers and robust risk mitigation plans.
• The API market is characterized by intense price competition due to genericization, with raw material costs, manufacturing scale, and regulatory compliance being the primary cost drivers.

Frequently Asked Questions

1. What is the typical lead time for procuring bulk pioglitazone hydrochloride API from a qualified manufacturer? Lead times can vary but typically range from 8 to 16 weeks from order placement to delivery, depending on the manufacturer's existing production schedule, raw material availability, and shipping logistics.

2. Are there any specific quality certifications beyond GMP that are highly valued for pioglitazone HCl API sourcing? While GMP is the foundational requirement, a strong audit history with major regulatory bodies (FDA, EMA, PMDA), a comprehensive quality management system, and well-documented process validation are highly valued. Certificates of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) are also significant.

3. What impact do raw material price fluctuations have on pioglitazone HCl API pricing? Raw material costs, particularly for key intermediates, can represent a significant portion of the API manufacturing cost. A sustained increase in precursor prices will generally lead to upward pressure on pioglitazone HCl API pricing, though this is often moderated by competitive market forces and long-term supply contracts.

4. How can a company ensure the long-term supply stability of pioglitazone HCl API from its chosen suppliers? Long-term supply stability is best ensured through diversified sourcing from multiple qualified suppliers across different geographies. Establishing strong, transparent relationships with suppliers, including robust supply agreements with clear performance clauses, and proactive communication regarding market demand and potential disruptions are also crucial.

5. What are the typical shelf life and storage conditions for pioglitazone hydrochloride API? The typical shelf life for pioglitazone hydrochloride API is generally 2 to 3 years when stored under controlled conditions. Recommended storage conditions usually involve keeping the API in tightly sealed containers, protected from light, moisture, and at controlled room temperature (e.g., 20-25°C or 15-30°C, as specified by the manufacturer).

Citations

[1] Dr. Reddy's Laboratories. (n.d.). API Manufacturing. Retrieved from https://www.drreddys.com/api-manufacturing/ [2] Laurus Labs. (n.d.). APIs. Retrieved from https://www.lauruslabs.com/apis/ [3] Divi's Laboratories. (n.d.). APIs. Retrieved from https://divis.com/apis [4] Aarti Drugs. (n.d.). Active Pharmaceutical Ingredients. Retrieved from https://www.aartidrugs.com/api-portfolio [5] Granules India. (n.d.). API Products. Retrieved from https://www.granulesindia.com/api-products [6] Zhejiang NHU Co., Ltd. (n.d.). Pharmaceuticals. Retrieved from https://www.neu.cn/en/pharmaceuticals/